Current patent status of histone deacetylase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 9, 2002, Pages 1375-1384

  Curtin, Michael L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

; ketoamides; trifluoromethyl ketones; Acetyldinaline; Acute promyelocytic leukaemia (APL); Antineoplastic; Antiprotozoal; Apicidin; Butyric acid; Cancer; Chromatin; CI 994; Depsipeptide; FK228; FR901228; HDAC inhibitor; HDAC like protein; Histone deacetylase (HDAC); Histone H4

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 4 PHENYLBUTYRIC ACID; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANTINEOPLASTIC AGENT; APICIDIN; BENZAMIDE DERIVATIVE; BUTYRIC ACID DERIVATIVE; CYCLOPEPTIDE; FR 901228; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; KETONE DERIVATIVE; KETOTHIOL; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PACLITAXEL; RETINOIC ACID; TETRAPEPTIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; CANCER; CANCER GROWTH; CANCER THERAPY; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; ONCOGENE; PATENT; PROMYELOCYTIC LEUKEMIA; PROTEIN TARGETING; REVIEW;

EID: 0036737592     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.9.1375     Document Type: Review

References (27)

1. Cheung WL, Briggs SD, Allis CD: Acetylation and chromosomal functions. Curr. Opin. Cell Biol. (2000) 12:326-333.
2. Vigushin DM, Coombes RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs (2002) 13:1-13.
3. Gray SG, Ekstrom TJ: The human histone deacetylase family. Exp. Cell Res. (2001) 262:75-83.
4. Kramer OH, Gottlicher M, Heinzel T: Histone deacetylase, as a therapeutic target. Trends in Endocrin. & Metab. (2001) 12:294-300.
5. Jung M: Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. (2001) 8:1505-1511.
6. Sternson SM, Wong JC, Grozinger CM, Schreiber SL: Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. (2001) 3:4239-4242.
7. Finnin MS, Donigian JR, Cohen A et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401:188-193.
8. Richon VM, Emiliani S, Verdin E et al.: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA (1998) 95:3003-3007.
9. Kelly WK, Richon V, Troso-Sandoval T et al.: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor: biologic activity without toxicity. Proc. Am. Soc. Clin. Oncol. (2001) 20(87a):344.
10. Jung M, Brosch G, Kolle D, Scherf H, Gerhauser. C, Loidl P: Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. (1999) 42:4669-4679.
11. Ohtani M, Matsuura T, Shirahase K, Sugita K: (2E)-5-[3-[(Phenylsulfonyl)aminol]phenyl]pent-2-en-4-ynohydroxamic acid and its derivatives as novel and potent inhibitors of ras transformation. J. Med. Chem. (1996) 39:2871-2873.
12. Kim YB, Lee K, Sugita K, Yoshida M, Horinouchi S: Oxamflatin is a novel antitumour compound that inhibits mammalian histone deacetylase. Oncogene (1999) 18:2461-2470.
13. Su GH, Sohn TA, Ryu B, Kern SE: A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. (2000) 60:3137-3142.
14. Lavoie R, Bouchain G, Frechette S et al.: Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med Chem. Lett. (2001) 11:2847-2850.
15. Meinke PT, Liberator P: Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr. Med. Chem. (2001) 8:211-235.
16. Singh SB, Zink DL, Liesch JM et al.: Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal (α-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J. Org. Chem. (2002) 67:815-825.
17. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S: Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA (2001) 98:87-92.
18. Sandor V, Bakke S, Robey RW et al.: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Canc. Res. (2002) 8:718-728.
19. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S: FR901228, a potent antitumour antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. (1998) 241:126-133.
20. Michaelides MR, Curtin ML: Recent advances in matrix meralloproteinase inhibitors research. Curr. Pharm. Design (1999) 5:787-819.
21. Saito A, Yamashita T, Mariko Y et al.: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumour activity against human tumours. Proc. Natl. Acad. Sci. USA (1999) 96:4592-4597.
22. Suzuki T Ando T, Tsuchiya K et al.: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. (1999) 42:3001-3003.
23. Seelig MH, Berger MR: Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Eur. J Cancer (1996) 32A:1968-1976.
24. Kraker AJ, Hartl BG, Miin J, Merriman RL: Effect of CI-994 (N-acetyl dinaline or 4-(acetylamino)-N-(2-amino-phenyl)benzamide) on histone acetylation and differentiation in HCT-8 colon carcinoma cells. Proc. Am. Assoc. Canc. Res. (1999) 40(90):121-122.
25. Prakash S, Foster BJ, Meyer M et al.: Chronic oral administration of CI-994: a Phase I study. Invest. New Drugs (2001) 19:1-11.
26. Warrell RP Jr, He L, Richon V, Calleja E, Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukaemia by use of an inhibitor of histone deacetylase. J. Nat. Canc. Inst. (1998) 90:1621-1625.
27. Rephaeli A, Zhuk R, Nudelman A: Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action and clinical applications. Drug Development Res. (2000) 50:379-391.